Pan JQ, Baez-Nieto D, Allen A, Wang HR, Cottrell JR. Developing High-Throughput Assays to Analyze and Screen Electrophysiological Phenotypes. Methods Mol Biol. 2018;1787:235-252. doi:10.1007/978-1-4939-7847-2_18
Fass DM, Reis SA, Ghosh B, et al. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology. 2013;64:81-96. doi:10.1016/j.neuropharm.2012.06.043
Diogo D, Tian C, Franklin CS, et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat Commun. 2018;9(1):4285. doi:10.1038/s41467-018-06540-3
Altmann KH, Buchner J, Kessler H, et al. The state of the art of chemical biology. Chembiochem. 2009;10(1):16-29. doi:10.1002/cbic.200800758
Wellington S, Hung DT. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets. ACS Infect Dis. 2018;4(5):696-714. doi:10.1021/acsinfecdis.7b00255
Dandapani S, Comer E, Duvall JR, Munoz B. Hits, leads and drugs against malaria through diversity-oriented synthesis. Future Med Chem. 2012;4(18):2279-94. doi:10.4155/fmc.12.178
Rohde JM, Brimacombe KR, Liu L, et al. Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors. Bioorg Med Chem. 2018;26(8):1727-1739. doi:10.1016/j.bmc.2018.02.016
Marcaurelle LA, Comer E, Dandapani S, et al. An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J Am Chem Soc. 2010;132(47):16962-76. doi:10.1021/ja105119r
Gerry CJ, Schreiber SL. Chemical probes and drug leads from advances in synthetic planning and methodology. Nat Rev Drug Discov. 2018;17(5):333-352. doi:10.1038/nrd.2018.53
Gupta-Ostermann D, Wawer M, Wassermann AM, Bajorath J. Graph mining for SAR transfer series. J Chem Inf Model. 2012;52(4):935-42. doi:10.1021/ci300071y